aldh9a1b Antibody

What is ALDH9A1 and what role does it play in cellular metabolism?

ALDH9A1 (aldehyde dehydrogenase 9 family, member A1) is an enzyme that catalyzes the dehydrogenation of gamma-aminobutyraldehyde to gamma-aminobutyric acid (GABA) . It demonstrates high activity for oxidizing gamma-aminobutyraldehyde and other amino aldehydes . The ALDH family more broadly plays major roles in the detoxification of alcohol-derived acetaldehyde and is involved in the metabolism of corticosteroids, biogenic amines, neurotransmitters, and products of lipid peroxidation . ALDH9A1 specifically contributes to important cellular processes related to aldehyde metabolism and detoxification of potentially harmful compounds.

What are the recommended applications for ALDH9A1 antibodies?

ALDH9A1 antibodies are validated for multiple experimental applications, with different dilution recommendations depending on the technique:

• Western Blot (WB): 1:500-1:2000 dilution

• Immunohistochemistry (IHC): 1:100-1:400 dilution

• Immunofluorescence (IF)/ICC: 1:50-1:500 dilution

It's important to note that optimal dilutions should be determined empirically for each new experimental system, as results may be sample-dependent . Published applications have confirmed ALDH9A1 antibody efficacy in Western blotting techniques across multiple studies .

What types of samples have been validated with ALDH9A1 antibodies?

ALDH9A1 antibodies have demonstrated reactivity with both human and mouse samples . In particular, ALDH9A1 antibodies have been validated in the following systems:

• Cell lines: NIH/3T3 cells and HEK-293 cells for Western blot applications

• Tissue samples: Human liver cancer tissue and human kidney tissue for IHC applications

• Cultured cells: HeLa cells for immunofluorescence applications

What is the difference between ALDH9A1 and other ALDH family members like ALDH1A1 and ALDH1B1?

While all belonging to the aldehyde dehydrogenase family, these enzymes have distinct functions:

• ALDH9A1: Primarily oxidizes gamma-aminobutyraldehyde and amino aldehydes; has a molecular weight of approximately 56 kDa (calculated) though often observed at 46 kDa on gels

• ALDH1A1: A cytosolic dehydrogenase that catalyzes irreversible oxidation of various aldehydes to carboxylic acids; particularly important in retinoic acid metabolism and detoxification of lipid peroxidation products like 4-hydroxynon-2-enal (HNE)

• ALDH1B1: Involved in alcohol-derived acetaldehyde detoxification and metabolism of various compounds including corticosteroids and biogenic amines

These distinctions are important when selecting the appropriate antibody for specific research questions.

What are the recommended protocols for using ALDH9A1 antibodies in immunohistochemistry?

For paraffin-embedded tissues, follow these methodological guidelines:

• Deparaffinize and rehydrate tissue sections

• Perform antigen retrieval using TE buffer pH 9.0 (recommended for ALDH9A1) or alternatively citrate buffer pH 6.0

• Block endogenous peroxidase activity and non-specific binding

• Apply primary ALDH9A1 antibody at 1:100-1:400 dilution

• Incubate at appropriate conditions (typically 4°C overnight or room temperature for 1-2 hours)

• Apply appropriate detection system

• Counterstain, dehydrate, and mount

Validation studies have shown effective staining in human liver cancer tissue and kidney tissue sections using these protocols .

How should researchers optimize Western blot protocols for ALDH9A1 detection?

For optimal Western blot results with ALDH9A1 antibodies:

• Prepare protein samples in appropriate lysis buffer with protease inhibitors

• Resolve proteins on 7.5-10% SDS-PAGE gels

• Transfer proteins to membrane using standard techniques

• Block with appropriate blocking buffer

• Incubate with ALDH9A1 primary antibody at 1:500-1:2000 dilution

• Wash thoroughly and incubate with appropriate secondary antibody

• Develop using chemiluminescence or other detection methods

Note that ALDH9A1 has a calculated molecular weight of 56 kDa, but is typically observed at approximately 46 kDa on Western blots . Researchers should verify band specificity using positive controls like NIH/3T3 or HEK-293 cell lysates.

What controls should be included when using ALDH9A1 antibodies?

Rigorous experimental design requires appropriate controls:

• Positive controls: Cell lines with confirmed ALDH9A1 expression (NIH/3T3, HEK-293, HeLa cells)

• Negative controls:

  • Primary antibody omission control

  • IgG isotype control at equivalent concentration

  • Tissues/cells known to not express ALDH9A1

• Knockdown/knockout validation: When possible, include ALDH9A1 siRNA or CRISPR knockout samples

• Overexpression validation: Include samples with forced ALDH9A1 expression

Research has validated ALDH9A1 knockdown and overexpression models in cell lines like A498 and CAKI-1, confirming antibody specificity via qRT-PCR and Western blotting .

What are common issues with ALDH9A1 antibody staining in IHC and how can they be resolved?

When troubleshooting immunohistochemical staining:

For ALDH9A1 specifically, antigen retrieval is critical as noted in the literature: "suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0" .

How can researchers verify ALDH9A1 antibody specificity?

To confirm antibody specificity:

• Compare staining patterns across multiple antibodies targeting different epitopes of ALDH9A1

• Perform peptide competition assays using the immunogen peptide

• Verify knockdown efficiency through siRNA approaches followed by Western blot analysis

• Use CRISPR/Cas9-mediated knockout cells as negative controls

• Employ overexpression systems with tagged ALDH9A1 constructs to confirm band identity

Research has validated these approaches: "The efficiency of overexpression and knockdown of ALDH9A1 was confirmed via qRT-PCR and western blotting assays" .

How can ALDH9A1 antibodies be utilized in protein-protein interaction studies?

For investigating ALDH9A1 protein interactions:

• Co-immunoprecipitation (Co-IP): Use anti-ALDH9A1 antibodies to precipitate protein complexes, followed by immunoblotting for potential binding partners

• Proximity ligation assays: Detect in situ protein interactions using ALDH9A1 antibodies paired with antibodies against suspected interaction partners

• Immunofluorescence co-localization: Perform dual staining with ALDH9A1 and partner protein antibodies

These approaches have been validated in research: "Endogenous ALDH9A1 was immunoprecipitated from cell lysates obtained from HEK293T cells, followed by successful immunoblotting for NPM1" . Additionally, "endogenously immunoprecipitated NPM1 also efficiently immunoblot for ALDH9A1" , confirming the utility of these antibodies in protein interaction studies.

What methodologies can be used to study ALDH9A1 post-translational modifications?

Advanced studies of ALDH9A1 post-translational modifications require:

• Immunoprecipitation with ALDH9A1 antibodies followed by mass spectrometry analysis

• Use of modification-specific antibodies (phospho-, acetyl-, etc.) in combination with ALDH9A1 immunoprecipitation

• Site-directed mutagenesis of putative modification sites combined with functional assays

• Comparison of modification patterns in different cellular contexts or disease states

Recent research has investigated N6-methyladenosine modification of ALDH9A1 and its impact on function, demonstrating the importance of studying such modifications .

How can ALDH9A1 antibodies be applied in cancer research models?

For cancer research applications:

• Expression profiling: Analyze ALDH9A1 expression across tumor tissues and corresponding normal tissues using IHC

• Prognostic marker evaluation: Correlate ALDH9A1 expression with patient outcomes

• Functional studies: Examine consequences of ALDH9A1 modulation on cancer cell behavior

• Mechanistic investigations: Identify signaling pathways influenced by ALDH9A1

Research has demonstrated: "Given that the expression of ALDH9A1 notably impacted the outcomes of patients with ccRCC, this study then delved into the unseen mechanism of ALDH9A1 in ccRCC" . Specifically, "CCK8 assays demonstrated that the exogenous increased ALDH9A1 notably damped cell proliferation" , and "The migration and invasion abilities were damped upon forced expressing of ALDH9A1 in ccRCC cells" .

How does ALDH9A1 expression correlate with other biomarkers in cancer studies?

Integrative analysis approaches for ALDH9A1 studies include:

• Multi-marker IHC panels combining ALDH9A1 with other prognostic markers

• Correlation analysis of ALDH9A1 expression with genomic alterations

• Integration of proteomics and transcriptomics data to identify co-regulated networks

Research has shown that ALDH9A1 interacts with other proteins like NPM1, which may have prognostic significance: "Along with molecules exhibiting significant prognostic value for ccRCC patients, we identified five potential candidates, namely HNRNPK, IMMT, CANX, NPM1, and SERBP1" .

What are the methodological considerations when comparing different ALDH family antibodies in the same experiment?

When using multiple ALDH family antibodies:

• Verify antibody cross-reactivity within the ALDH family

• Optimize each antibody independently before multiplexing

• Consider sequential rather than simultaneous staining for closely related family members

• Use appropriate controls for each antibody

• Select detection systems that allow clear distinction between signals

The search results indicate structural and functional differences between ALDH9A1, ALDH1A1, and ALDH1B1 that researchers should consider when designing comparative experiments .

How can chromatin immunoprecipitation (ChIP) be performed using transcription factors that regulate ALDH9A1?

For ChIP studies examining ALDH9A1 regulation:

• Use commercial ChIP kits with protocol optimization: "The ChIP assay was performed with the SimpleChIP Enzymatic Chromatin IP Kit (Agarose Beads) from Cell Signaling Technology (#9002, Boston, USA), following the manufacturer's instructions"

• Select appropriate antibodies against transcription factors of interest

• Design primers targeting the ALDH9A1 promoter region

• Include appropriate controls: "Enrichment levels were normalized against the IgG control"

• Validate findings with reporter assays or expression studies

The methodology can be based on established protocols: "Immunoprecipitation was conducted using anti-NPM1 antibody (Proteintech, #60096-1-lg, Hubei, China) or normal IgG (#2729, Cell Signaling Technology). Quantitative PCR (qPCR) was employed to investigate the potential DNA-binding sites" .

How might ALDH9A1 antibodies be applied in studying metabolic disorders?

Given ALDH9A1's role in metabolism, research applications could include:

• Examining ALDH9A1 expression changes in metabolic disease tissues

• Investigating post-translational modifications affecting enzyme activity

• Exploring relationships between ALDH9A1 and lipid metabolism pathways

• Developing therapeutic approaches targeting ALDH9A1

Recent research suggests connections between ALDH9A1 and lipid metabolism: "N6-methyladenosine-modified ALDH9A1 modulates lipid metabolism" , opening avenues for metabolic disorder research.

What are emerging techniques for studying ALDH9A1 localization and trafficking?

Advanced microscopy approaches include:

• Super-resolution microscopy for nanoscale localization

• Live-cell imaging to track ALDH9A1 dynamics

• Proximity labeling techniques (BioID, APEX) to map the protein's microenvironment

• Subcellular fractionation combined with immunoblotting: "The nuclear and cytoplasmic protein extraction kit (#P0028, Beyotime) was utilized to isolate the cytosolic fraction and nuclear fraction using the guidelines provided by the manufacturer"

These techniques can provide insights into ALDH9A1's subcellular localization and potential functional compartmentalization.

How can structural biology approaches complement antibody-based studies of ALDH9A1?

Integrative structural approaches include:

• Using antibodies in conjunction with cryo-EM studies

• Epitope mapping to correlate antibody binding with structural features

• Protein-protein docking simulations: "The ZDOCK server was conducted to predict interaction based on the 3D structure of protein complexes, which was further refined by electrostatics, desolvation-free energy, and shape complementarity"

• Structure-guided design of more specific antibodies